Overview

Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and Digoxin

Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
To assess the influence of multiple doses of BI 425809 on single dose pharmacokinetics of midazolam (CYP3A4 probe drug), warfarin (CYP2C9 probe drug), omeprazole (CYP2C19 probe drug) and digoxin (P-gp probe drug)
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
BI 425809
Digoxin
Midazolam
Omeprazole
Warfarin